- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03904849
Cannabidiol for Alcohol Use Disorder
October 9, 2019 updated by: Medical University of South Carolina
A Pilot Human Laboratory Study of Cannabidiol in Alcohol Use Disorder
The purpose of this study is to determine whether cannabidiol, relative to placebo, affects subjective response to alcohol or alcohol drinking.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This study will examine the effects of Epidiolex among adults who drink alcohol heavily but who are not seeking treatment for their alcohol use.
Epidiolex is an FDA-approved formulation of cannabidiol, the primary non-psychoactive constituent of cannabis.
Participants in the study will be randomly assigned to take Epidiolex or placebo for 8 days.
There are 3 study visits, including a day-long visit in the laboratory.
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder, as assessed by the Structured Clinical Interview for DSM-5 (SCID-5).
- Reports drinking, on average, at least 20 standard alcoholic drinks per week for at least the past 3 months, with at least 5 standard alcoholic drinks during a drinking episode at least once per week during the past 3 months.
- Currently not engaged in, and does not want treatment for, alcohol-related problems.
- Age 21-40.
- Able to read and understand questionnaires and informed consent.
- Lives within 50 miles of the study site.
Exclusion Criteria:
- Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
- Any psychoactive substance use (including cannabis, but excluding nicotine) within 30 days prior to screening, as indicated by self-report and urine drug screen.
- Any cannabidiol use, in any formulation (e.g., oral, topical) within 30 days prior to screening.
- Current DSM-5 Axis I diagnosis, including major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar affective disorder, schizophrenia, dissociative disorders, eating disorders, or any other psychotic or organic mental disorder.
- Current active suicidal ideation, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Current use of any psychoactive medication, any medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate), and/or antiepileptic medications (e.g., valproate).
- Current use of any known hepatotoxic medication.
- Current use of strong or moderate CYP3A4 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include protease inhibitors, macrolide antibiotics [e.g., erythromycin], azole antifungals [e.g., ketoconazole], verapamil, and grapefruit juice).
- Current use of strong or moderate CYP2C19 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include proton pump inhibitors [e.g., omeprazole, lansoprazole], prednisone, and norethisterone).
- History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
- Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems that would impair participation or limit medication ingestion.
- Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
- Current or past hepatocellular disease, as indicated by: a) verbal report; b) Child-Pugh score > 6 (i.e., Child-Pugh class B or C); or c) alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin greater than the upper limit of the normal range at screening.
- Females of childbearing potential who are pregnant (by serum HCG), nursing, or who are not using a reliable form of birth control.
- Current charges pending for a violent crime (not including driving under the influence-related offenses).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cannabidiol
Cannabidiol 6 mL of 100 mg/mL cannabidiol oral solution per day for 8 days
|
Cannabidiol oral solution
Other Names:
|
Placebo Comparator: Placebo
Placebo 6 mL oral solution per day for 8 days
|
Placebo oral solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average alcohol-induced sedation after medication ingestion
Time Frame: Average of measurements obtained 30, 60, 90, and 120 minutes following alcohol administration in the lab. Alcohol will be administered 2.5 hours after ingestion of study medication.
|
Biphasic Alcohol Effects Scale sedation subscale score (range = 0-70; higher scores = greater sedation)
|
Average of measurements obtained 30, 60, 90, and 120 minutes following alcohol administration in the lab. Alcohol will be administered 2.5 hours after ingestion of study medication.
|
Average subjective response to alcohol after medication ingestion
Time Frame: Average of measurements obtained 30, 60, 90, and 120 minutes following alcohol administration in the lab. Alcohol will be administered 2.5 hours after ingestion of study medication.
|
Subjective High Assessment Scale score (range = 0-130; higher scores = greater intoxication)
|
Average of measurements obtained 30, 60, 90, and 120 minutes following alcohol administration in the lab. Alcohol will be administered 2.5 hours after ingestion of study medication.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol drinking in natural environment
Time Frame: 8 days of medication ingestion.
|
Total number of standard drinks per day consumed during natural (usual environment) conditions
|
8 days of medication ingestion.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Joseph P Schacht, PhD, Medical University of South Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2019
Primary Completion (Anticipated)
April 30, 2020
Study Completion (Anticipated)
April 30, 2020
Study Registration Dates
First Submitted
April 2, 2019
First Submitted That Met QC Criteria
April 3, 2019
First Posted (Actual)
April 5, 2019
Study Record Updates
Last Update Posted (Actual)
October 11, 2019
Last Update Submitted That Met QC Criteria
October 9, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00086168
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
University Hospital, Basel, SwitzerlandSolidarMedRecruitingAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateLesotho
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States